Pulmocide
Latest round
- Series C
Last raised
- Dec 2022
Total raised
- $165M
Investors
- 13
About Pulmocide
Pulmocide Limited, founded in 2013, is headquartered in London, UK, and specializes in developing antifungal treatments for respiratory diseases. The company's lead product, opelconazole, is currently undergoing Phase 3 clinical trials.Pulmocide primarily develops innovative inhaled antifungal therapies aimed at addressing serious respiratory diseases, with a particular focus on difficult-to-treat conditions such as invasive pulmonary aspergillosis. Its lead product, opelconazole, is designed to deliver high concentrations of the drug directly to the lungs, targeting fungal infections while minimizing systemic exposure. This investigational product is currently in a Phase 3 clinical trial and is intended for patients who do not respond adequately to standard antifungal treatments.80. Pulmocide aims to expand its reach within the US and EU markets, targeting opportunities for new product launches and enhancements in treatment options for respiratory diseases.
Who invested in Pulmocide
13 investors across 4 rounds
See all investors in Pulmocide
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Pulmocide
Who invested in Pulmocide?
Pulmocide has 13 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pulmocide raised?
Pulmocide has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Pulmocide last raise money?
Pulmocide's most recent round on record is a Series C, in Dec 2022.
What does Pulmocide do?
Pulmocide Limited, founded in 2013, is headquartered in London, UK, and specializes in developing antifungal treatments for respiratory diseases.
Where is Pulmocide headquartered?
Pulmocide is headquartered in London, UK.
Which VCs invest in companies like Pulmocide?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at Pulmocide's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Pulmocide? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.